This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, X. Articles by Kappes, J. C. Search for Related Content PubMed PubMed Citation Articles by Wu, X. Articles by Kappes, J. C.

 Previous Article  |  Next Article 

J. Virol., Jun 1996, 3378-3384, Vol 70, No. 6
Copyright © 1996, American Society for Microbiology

Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles

X Wu, H Liu, H Xiao, JA Conway and JC Kappes
Department of Medicine, University of Alabama at Birmingham, 35294, USA.

The human immunodeficiency virus type I (HIV-1) Vpr and HIV-2 Vpx proteins package into virions through interactions with their cognate Gag polyprotein precursor. The targeting properties of Vpr and Vpx have been exploited to incorporate foreign proteins into virions by expression as heterologous fusion molecules (X. Wu, H.-M. Liu, H. Xiao, J. Kim, P. Seshaiah, G. Natsoulis, J. D. Boeke, B. H. Hahn, and J. C. Kappes, J. Virol. 69:3389-3398, 1995). To explore the possibility of utilizing Vpx and Vpr to target dominant negative mutants of the HIV Pol proteins into virions, we fused HIV-2 Vpx with an enzymatically defective protease (PR) mutant. Using a vector system to facilitate transient coexpression with HIV provirus, Vpx-PR-mutant (VpxPR(M)) fusion protein was expressed and packaged efficiently into HIV-2 and simian immunodeficiency virus virions. Immunoblot analysis of purified virions demonstrated that the packaging of VpxPR(M) interfered with the processing of the Gag and Gag/Pol precursor proteins, similar to that of a well-characterized active-site PR inhibitor. The incomplete processing of Gag and Gag/Pol was consistent with a 25-fold reduction in virion infectivity. The coexpression of a packaging defective VpxPR(M) fusion protein with HIV-2 provirus produced virions with fully processed Gag protein, similar to wild-type virions. Importantly, virions trans complemented with a Vpx-chloramphenicol acetyltransferase fusion protein were normal with respect to the processing of Gag protein and the ability to infect and replicate in vitro. These results indicate that VpxPR(M) specifically inhibited the function of the viral protease and provide for the first time proof of principle that the incorporation of foreign proteins into virions via fusion with Vpx can inhibit HIV replication. The use of accessory proteins as vehicles to deliver deleterious proteins to virions, including dominant negative mutants of Pol proteins, may provide new opportunities for application of gene therapy-based antiretroviral strategies. The ability to package PR by expression in trans, independent of the Gag/Pol precursor, also represents a novel approach that may be exploited to study the function of the Pol proteins.

This article has been cited by other articles:

• Luckay, A., Sidhu, M. K., Kjeken, R., Megati, S., Chong, S.-Y., Roopchand, V., Garcia-Hand, D., Abdullah, R., Braun, R., Montefiori, D. C., Rosati, M., Felber, B. K., Pavlakis, G. N., Mathiesen, I., Israel, Z. R., Eldridge, J. H., Egan, M. A. (2007). Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques. J. Virol. 81: 5257-5269 [Abstract] [Full Text]  
• Jenkins, Y., Pornillos, O., Rich, R. L., Myszka, D. G., Sundquist, W. I., Malim, M. H. (2001). Biochemical Analyses of the Interactions between Human Immunodeficiency Virus Type 1 Vpr and p6Gag. J. Virol. 75: 10537-10542 [Abstract] [Full Text]  
• Schumann, G., Hermankova, M., Cannon, K., Mankowski, J. L., Boeke, J. D. (2001). Therapeutic Effect of a Gag-Nuclease Fusion Protein against Retroviral Infection In Vivo. J. Virol. 75: 7030-7041 [Abstract] [Full Text]  
• Serio, D., Singh, S. P., Cartas, M. A., Weber, I. T., Harrison, R. W., Louis, J. M., Srinivasan, A. (2000). Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease. Protein Eng Des Sel 13: 431-436 [Abstract] [Full Text]  
• Wu, X., Liu, H., Xiao, H., Conway, J. A., Hehl, E., Kalpana, G. V., Prasad, V., Kappes, J. C. (1999). Human Immunodeficiency Virus Type 1 Integrase Protein Promotes Reverse Transcription through Specific Interactions with the Nucleoprotein Reverse Transcription Complex. J. Virol. 73: 2126-2135 [Abstract] [Full Text]  
• Okui, N., Kobayashi, N., Kitamura, Y. (1998). Production of Uninfectious Human Immunodeficiency Virus Type 1 Containing Viral Protein R Fused to a Single-Chain Antibody against Viral Integrase. J. Virol. 72: 6960-6964 [Abstract] [Full Text]  
• Kobinger, G. P., Borsetti, A., Nie, Z., Mercier, J., Daniel, N., Gottlinger, H. G., Cohen, E. A. (1998). Virion-Targeted Viral Inactivation of Human Immunodeficiency Virus Type 1 by Using Vpr Fusion Proteins. J. Virol. 72: 5441-5448 [Abstract] [Full Text]  
• Serio, D., Rizvi, T. A., Cartas, M., Kalyanaraman, V. S., Weber, I. T., Koprowski, H., Srinivasan, A. (1997). Development of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc. Natl. Acad. Sci. USA 94: 3346-3351 [Abstract] [Full Text]